Cortical inhibition function is associated with baseline suicidal symptoms and post-ketamine suicidal symptom reduction among patients with treatment-resistant depression and strong suicidal ideation-Reference-Cited by-同舟云学术

Cortical inhibition function is associated with baseline suicidal symptoms and post-ketamine suicidal symptom reduction among patients with treatment-resistant depression and strong suicidal ideation

Published:2023-05 Issue: Volume:161 Page:48-53
ISSN:0022-3956
Container-title:Journal of Psychiatric Research
language:en
Short-container-title:Journal of Psychiatric Research

Author:

Chen Mu-Hong^ORCID,Su Tung-Ping,Chen Li-Fen,Li Cheng-Ta,Wu Hui-Ju,Lin Wei-Chen,Tsai Shih-Jen,Bai Ya-Mei,Mao Wei-Chung,Tu Pei-Chi,Jeng Jia-Shyun,Li Wei-Chi

Publisher

Elsevier BV

Subject

Biological Psychiatry,Psychiatry and Mental health

Reference36 articles.

1. Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial;Abbar;BMJ,2022

2. Ketamine for depression, 1: clinical summary of issues related to efficacy, adverse effects, and mechanism of action;Andrade;J. Clin. Psychiatry,2017

3. Evidence for impaired cortical inhibition in patients with unipolar major depression;Bajbouj;Biol. Psychiatr.,2006

4. Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant;Ballard;J. Psychiatr. Res.,2015

5. A participant-level integrative data analysis of differential placebo response for suicidal ideation and nonsuicidal depressive symptoms in clinical trials of intravenous racemic ketamine;Bloomfield-Clagett;Int. J. Neuropsychopharmacol.,2022

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Depressionen: Ketamininfusionen bei Therapieresistenz und Suizidalität?;Fortschritte der Neurologie · Psychiatrie;2024-01

2. Effects of low-dose ketamine infusion on vascular endothelial growth factor and matrix metalloproteinase-9 among patients with treatment-resistant depression and suicidal ideation;Journal of Psychiatric Research;2023-09

3. Borneol-modified PEGylated graphene oxide as a nanocarrier for brain-targeted delivery of ginsenoside Rg1 against depression;International Journal of Pharmaceutics;2023-08